問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Dermatology

更新時間：2023-09-19

趙曉秋
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

趙曉秋

National Taiwan University Hospital

Division of Dermatology

List

8Cases

2018-10-01 - 2020-02-28

Phase III

Completed
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    PF-04965842

Participate Sites
6Sites

Terminated6Sites

陳志強
Taipei Veterans General Hospital

Division of Dermatology

2025-03-01 - 2027-08-31

Phase II

Active
A Phase 2, multicenter, multiple-dose, monotherapy study to evaluate the safety of OBI-858 in participants with moderate to severe glabellar lines.

  • Condition/Disease

    Moderate to severe glabellar lines

  • Test Drug

    OBI-858

Participate Sites
5Sites

Recruiting5Sites

2008-12-17 - 2009-12-20

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-03-16 - 2013-03-16

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2014-11-01 - 2020-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis

  • Condition/Disease

    Moderate to Severe Plaque-type Psoriasis

  • Test Drug

    CNTO1959(guselkumab)

Participate Sites
5Sites

Terminated5Sites

2013-11-29 - 2013-11-29

Phase II

A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.

  • Condition/Disease

    Common Warts / Verruca Vulgaris (CWs)

  • Test Drug

    SR-T100

Participate Sites
4Sites

Study ended4Sites

2014-01-01 - 2018-07-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-06-01 - 2014-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB